{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE305nnn/GSE305825/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305825"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Golcadomide with CD20 T-cell engager extends survival in lymphoma model by boosting T-cell activation and trafficking","description":"Despite recent clinical advances in the treatment of diffuse large B-cell lymphoma, relapsed/refractory patients remain an unmet medical need. Immune-based therapies, such as CAR T and T cell bispecific antibodies, redirect T-cells to target antigens expressed on the malignant cells, have demonstrated promising antitumor and clinical activity. However, even with these advanced therapies some patients do not have non-durable responses, potentially due to tumor microenvironment factors such as lack of T-cell infiltration. Golcadomide, a potential first-in-class Aiolos and Ikaros degrading CRBN E3 ligase modulator (CELMoD), has a multifaceted mechanism of action, including direct antitumor effects and T-cell activation. This study demonstrates that through specific degradation of transcription factors, Aiolos and Ikaros, golcadomide enhances T-cell function through increased proliferation and cytokine production. Spatial transcriptomic and multiplex immunofluorescence data revealed that single agent golcadomide treatment enhanced T-cell functions in a syngeneic GEMM lymphoma model, including T-cell activation and trafficking to the TME, suggesting potential synergy with T-cell engagers. In a combination with a CD20xCD3 murine surrogate T-cell engager, golcadomide increased T-cell mediated cytotoxicity against lymphoma cells and extended survival in an aggressive lymphoma GEMM compared to single-agent bispecific treatment. These findings support the clinical rationale for combining these immunotherapeutic modalities to improve outcomes in DLBCL.","dates":{"publication":"2026/08/18"},"accession":"GSE305825","cross_references":{"GSM":["GSM9185830","GSM9185797","GSM9185796","GSM9185827","GSM9185805","GSM9185804","GSM9185826","GSM9185825","GSM9185803","GSM9185824","GSM9185802","GSM9185801","GSM9185823","GSM9185822","GSM9185800","GSM9185821","GSM9185843","GSM9185842","GSM9185820","GSM9185809","GSM9185808","GSM9185807","GSM9185829","GSM9185828","GSM9185806","GSM9185841","GSM9185840","GSM9185816","GSM9185838","GSM9185815","GSM9185837","GSM9185836","GSM9185814","GSM9185813","GSM9185835","GSM9185834","GSM9185812","GSM9185833","GSM9185811","GSM9185810","GSM9185799","GSM9185832","GSM9185831","GSM9185798","GSM9185819","GSM9185818","GSM9185839","GSM9185817"],"GPL":["20301"],"GSE":["305825"],"taxon":["Homo sapiens"]}}